New brain research could reshape our understanding of ADHD and the most common drugs that treat it.
With an expiration date still more than a year away, here's what the latest details reveal.
The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...
The use of medications for Attention-Deficit Hyperactivity Disorder (ADHD) has increased substantially across Europe over the ...
From 2022 to 2024, stimulant prescriptions issued in Connecticut increased by 13.2 percent, according to data from the state.
It has long been assumed that psychostimulants help those with ADHD by acting on the brain’s attention circuitry. However, ...
Long-term methylphenidate use in childhood links to higher adult BMI and slightly shorter height, underscoring the need for ...
Seoul National University Hospital researchers have linked childhood attention-deficit/hyperactivity disorder and ...
This article was reviewed by Lynn Marie Morski, MD, JD. Key Takeaways: ADHD and menopause symptoms can overlap, and one ...
Matthew Lock, who was a Labour councillor for Maghull and Lydiate, died in 2023 aged 19.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results